{"success":true,"data":{"pressRelease":{"id":"159033","rtpr_id":"nWkr6Q0Nsc-20261002","ticker":"HLUNA","exchange":"Nasdaq Copenhagen","all_tickers":["HLUNA"],"title":"Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026","author":"Cision","published_at":"2026-10-02T06:00:11.596Z","article_body":"H. Lundbeck A/S* Late-breaking Phase III MASCOT oral presentation will\ncharacterize the clinical profile and diversity of participants in\nLundbeck’s ongoing global Phase III trial investigating amlenetug in\nmultiple system atrophy (MSA)\n* New research across clinical trial endpoints, biomarkers, diagnostic tools\nand healthcare burden underscores Lundbeck’s expanding scientific program in\nMSA\n* Exploratory Phase Ib data for Lu AF28996 investigating difficult-to-treat\nmotor complications in people with advanced Parkinson's disease\nValby, Denmark, 2 October 2026 – H. Lundbeck A/S (Lundbeck) today announced\nthat data from its movement disorders pipeline will be presented at the\nInternational Congress of Parkinson’s disease and Movement Disorders® (MDS)\n2026, taking place in Seoul, South Korea (4-8 October).\n\nThe presentations span MSA, a rare and rapidly progressing neurodegenerative\ndisease, and advanced Parkinson’s disease (PD), where motor complications\nremain difficult to control despite optimized treatment. Together, the data\nreflect Lundbeck’s growing scientific focus in movement disorders and its\ncommitment to advancing innovation in areas where significant unmet need\nremains.\n\nA key highlight will be a late-breaking oral presentation describing the\nbaseline characteristics of participants enrolled in MASCOT (NCT06706622), the\nongoing Phase III trial of amlenetug in MSA. MASCOT enrolled 401 participants\nwith clinically probable or clinically established MSA, including people with\nboth MSA-C and MSA-P, representing a broad spectrum of people living with the\ndisease. The trial is evaluating the safety and efficacy of amlenetug versus\nplacebo over a 72-week double-blind treatment period, with results expected in\nQ3 2027.\n\n“Movement disorders such as MSA and Parkinson’s disease remain among the\nmost complex and high-need areas in neuroscience,” said Tarek Samad,\nExecutive Vice President and Head of Research & Development at Lundbeck.\n“The breadth of research we are presenting at MDS reflects our commitment to\nadvancing potential new medicines while strengthening the scientific\nunderstanding of the biomarkers and clinical tools needed to support progress\nfor patients.”\n\nLundbeck will present additional research addressing important challenges in\nMSA clinical development. These include analyses supporting the use of the\nmodified Unified Multiple System Atrophy Rating Scale Part I, or mUMSARS Part\nI, as a clinical trial endpoint designed to measure functional decline in\npeople with MSA; validation of the Chinese version of UMSARS for use in\nclinical trials; and research into cerebrospinal fluid biomarkers that may\nsupport disease detection, differential diagnosis and monitoring.\n\nThe MSA program also includes new data highlighting the broader burden of MSA.\nA US observational database study found significantly higher healthcare costs\nand healthcare resource utilization among people with MSA compared with people\nwith Parkinson’s disease, underscoring the intensive care requirements\nassociated with this rapidly progressing disease.\n\nExploratory clinical data in advanced Parkinson’s disease\nLundbeck will also present new Phase Ib data for Lu AF28996, an\ninvestigational, novel, oral D1-like/D2-like dopamine receptor agonist being\ndeveloped for people with advanced Parkinson’s disease experiencing motor\ncomplications.\n\nThe 18-week open-label Phase Ib trial evaluated safety, tolerability and\nclinical effects in people with inadequately controlled advanced PD\nexperiencing motor fluctuations, with or without dyskinesia (involuntary\nmovements).\n\nThe clinical findings will be complemented by preclinical data exploring the\nrelationship between dose, motor efficacy and dyskinesia in a primate model of\nParkinson’s disease (MPTP-macaque).\n\nLu AF28996 and amlenetug are investigational compounds and have not been\napproved for use by any regulatory authority. Their efficacy and safety have\nnot been established.\n\nLundbeck’s scientific program at MDS:\n\n Data presentations \n Therapeutic  area Presentation content Presentation Type Details \n Multiple system atrophy (MSA)Amlenetug MSA CSF Biomarker Identification: Identification of Candidate Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Using Mass Spectrometry Based Proteomics in CSF Biobank Samples De novo; ePoster (121): Presenter:Pekka Kallunki 4 Oct 13:00-14:00 KST  Hall D, Station 2 Presentation order: 1 \n Multiple system atrophy (MSA)Amlenetug MSA US Healthcare Resource Utilization: Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study De novo; ePoster      (243): Presenter:Amar Mehta 4 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 1 \n Multiple system atrophy (MSA)Amlenetug Chinese UMSARS validation:Validation of the Chinese Version of the Unified Multiple System Atrophy Rating Scale De novo; ePoster      (150): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 5 \n Multiple system atrophy (MSA)Amlenetug Modified UMSARS Psychometrics:Psychometric Assessment of a Modified Version of the Unified Multiple System Atrophy Rating Scale Part I De novo; ePoster      (149): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 4 \n Multiple system atrophy (MSA)Amlenetug MASCOT trial baseline characteristics: Baseline characteristics of a Phase III double-blind, randomized trial of amlenetug for the treatment of multiple system atrophy Late breaker oral presentation; (OPP3): Presenter:Lotte Kjærsgaard 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 11 \n Multiple system atrophy (MSA)Amlenetug CSF α-Synuclein Assay to Differentiate MSA from PD: A CSF C Terminal α Synuclein Assay to Differentiate Multiple System Atrophy From Parkinson’s Disease Oral presentation; (OPP3-G): Presenter:Pekka Kallunki 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 7 \n Parkinson’s disease Lu AF28996  Ph Ib Part B HLR: Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, Results from an 18-week open-label, Phase 1b Trial De novo; ePoster (732)Presenter:Alberto Cucca 6 Oct 09:30-10:30 KST  Hall D, Station 12 \n Presentation order: 4 \n Parkinson’s disease Lu AF28996  Pre-clinical macaque data: Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Reduced Dyskinesia in the MPTP-Macaque Model De novo; ePoster (803) Presenter:Hanna Lindgren 6 Oct 09:30-10:30 KST  Hall D, Station 12 Presentation order: 3 \n\n Sponsored scientific symposium and forum presentation \n Therapeutic area Title Speakers Details \n Multiple system atrophy (MSA) Decoding MSA: From prodromal signs to clinical progression and integrative biomarkers Wassilios Meissner, Horacio Kaufmann Hirohisa Watanabe 5 Oct 12:15-13:15 KSTVenue: ASEM Ballroom 203, 2nd floor \n\n \n\nAbout Multiple System Atrophy (MSA)\nMSA is a rapidly progressing rare condition that causes damage to nerve cells\nin the brain. In a person with MSA, an abnormal build-up of the protein\nα-synuclein is thought to be responsible for damaging the areas of the brain\nthat control balance, movement, and the body's normal functions.(1) MSA is\nseriously debilitating and places a high disease burden on patients. There is\ncurrently no cure for MSA and no available treatment to slow its clinical\nprogression.(2)\n\nSymptoms of MSA usually start between 55 and 60 years of age, and the typical\ntime to death is 8.6 years after symptom onset.(2) Although there are many\ndifferent possible symptoms of MSA, not everyone who is affected will\nexperience all of them. The symptoms of MSA are wide-ranging and include\nmuscle control problems, similar to those of Parkinson's disease.(2) Many\ndifferent functions of the body can be affected, and symptoms including\nurinary incontinence, frequent falling, and unintelligible speech occur within\n3 years of disease onset. MSA is accompanied by reduced capacity to live\nindependently, and death is often due to respiratory problems.\n\nAbout amlenetug \nAmlenetug is a human monoclonal antibody (mAb) that recognizes and binds to\nall major forms of extracellular α-synuclein and thereby intended to prevent\nuptake and inhibit seeding of aggregation. Amlenetug is being developed by\nLundbeck under a joint research and licensing agreement between Lundbeck and\nGenmab A/S.\n\nAbout the MASCOT trial\nMASCOT (NCT06706622) is a Phase III interventional, randomized, double-blind,\nparallel-group, placebo-controlled, optional open-label extension trial that\nwill be conducted in North America, Europe, Asia and Australia.(3)\n\nThe trial comprises two parts: A double-blind period where participants are\nrandomized to receive either high or low doses of amlenetug, or placebo for 72\nweeks, followed by an open-label extension period where all participants\nenrolled in the trial are offered treatment with amlenetug. The aim of the\ntrial is to evaluate the efficacy, safety, and tolerability of amlenetug in\npatients with MSA. Amlenetug is delivered as an intravenous infusion every\nfour weeks.\n\nAbout Parkinson’s disease\nParkinson’s disease is a progressive and disabling neurological disease\ncharacterized by motor symptoms including slowness of movement, tremor and\nrigidity, as well as a range of non-motor symptoms.(4,5)\n\nThere are currently no established treatments that modify the progression of\nPD, and levodopa remains a cornerstone of symptomatic treatment.(6) With\nlong-term levodopa treatment, many people develop motor complications,\nincluding periods when symptoms return or worsen (“OFF-time”) and\ndyskinesia (involuntary movements), which can significantly affect daily\nfunctioning and quality of life.(4-7)\n\nPD is the second most common neurodegenerative disease after Alzheimer’s\ndisease and the most common movement disorder.(7-8) In 2021, an estimated\n11.77 million people worldwide were living with PD, and its prevalence is\nprojected to more than double by 2050.(9) As PD progresses, functional\nindependence can decline and reliance on caregivers and healthcare systems can\nincrease, contributing to a substantial personal, societal and economic\nburden.\n\nAbout Lu AF28996 \nLu AF28996 is an investigational, novel and oral prodrug of a\nD(1)-like/D(2)-like dopamine receptor agonist, with a pharmacologic profile\nthat may enhance dopaminergic striatal signaling in a prolonged manner. It is\nbeing investigated for its potential to improve motor fluctuations and\nlevodopa-induced dyskinesia in people with Parkinson’s disease. Concerted\nactivation of D1- and D2-like dopamine receptors may play an important role in\nmotor control.\n\nLu AF28996 is currently in Phase II clinical development. The DARE2 trial\n(NCT07514858) is evaluating its efficacy, safety and tolerability in adults\nwith Parkinson’s disease experiencing motor fluctuations despite optimized\nnon-invasive symptomatic treatment.(10)\n\nContacts\n\n Anders Crillsen Jens Høyer \n Senior Director, External & Internal Relations Vice President, Head of Investor Relations \n AECE@lundbeck.com JSHR@lundbeck.com \n +45 27 79 12 86 +45 30 83 45 01 \n \n \n \nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn (https://www.linkedin.com/company/lundbeck/).\n\nReferences:\n1. Jellinger KA. J Alzheimers Dis. 2018;62:1141–79\n2. Palma JA, et al. Auton Neurosci. 2018;211:15–25\n3. https://clinicaltrials.gov/study/NCT06706622?intr=Lu%20AF82422&rank=2\n4. Stocchi F, et al. Nat Rev Neurol 2024;20:695–707\n5. Heim B and Poewe W. J Parkinsons Dis 2025;23\n6. Cenci MA. Front Neurol 2014;5:242\n7. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912\n8. GBD. Global, regional, and national burden of neurological disorders during\n1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.\nLancet Neurol 2017;16:877–897\n9. Luo Y, et al. Front Aging Neurosci 2025;16:1498756.\n10.\nhttps://clinicaltrials.gov/study/NCT07514858?term=nct07514858%20&viewType=Card&rank=1\n \nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-showcase-progress-across-its-movement-disorders-pipeline-with-data-in-multiple-system-at%2Cc4403628\n\nMDS 2026 Final (https://mb.cision.com/Main/18215/4403628/4298745.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr6Q0Nsc-20261002","title":"Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026","author":"Cision","ticker":"HLUNA","created":"2026-10-02T06:00:11.596Z","tickers":["HLUNA"],"exchange":"Nasdaq Copenhagen","article_body":"H. Lundbeck A/S* Late-breaking Phase III MASCOT oral presentation will\ncharacterize the clinical profile and diversity of participants in\nLundbeck’s ongoing global Phase III trial investigating amlenetug in\nmultiple system atrophy (MSA)\n* New research across clinical trial endpoints, biomarkers, diagnostic tools\nand healthcare burden underscores Lundbeck’s expanding scientific program in\nMSA\n* Exploratory Phase Ib data for Lu AF28996 investigating difficult-to-treat\nmotor complications in people with advanced Parkinson's disease\nValby, Denmark, 2 October 2026 – H. Lundbeck A/S (Lundbeck) today announced\nthat data from its movement disorders pipeline will be presented at the\nInternational Congress of Parkinson’s disease and Movement Disorders® (MDS)\n2026, taking place in Seoul, South Korea (4-8 October).\n\nThe presentations span MSA, a rare and rapidly progressing neurodegenerative\ndisease, and advanced Parkinson’s disease (PD), where motor complications\nremain difficult to control despite optimized treatment. Together, the data\nreflect Lundbeck’s growing scientific focus in movement disorders and its\ncommitment to advancing innovation in areas where significant unmet need\nremains.\n\nA key highlight will be a late-breaking oral presentation describing the\nbaseline characteristics of participants enrolled in MASCOT (NCT06706622), the\nongoing Phase III trial of amlenetug in MSA. MASCOT enrolled 401 participants\nwith clinically probable or clinically established MSA, including people with\nboth MSA-C and MSA-P, representing a broad spectrum of people living with the\ndisease. The trial is evaluating the safety and efficacy of amlenetug versus\nplacebo over a 72-week double-blind treatment period, with results expected in\nQ3 2027.\n\n“Movement disorders such as MSA and Parkinson’s disease remain among the\nmost complex and high-need areas in neuroscience,” said Tarek Samad,\nExecutive Vice President and Head of Research & Development at Lundbeck.\n“The breadth of research we are presenting at MDS reflects our commitment to\nadvancing potential new medicines while strengthening the scientific\nunderstanding of the biomarkers and clinical tools needed to support progress\nfor patients.”\n\nLundbeck will present additional research addressing important challenges in\nMSA clinical development. These include analyses supporting the use of the\nmodified Unified Multiple System Atrophy Rating Scale Part I, or mUMSARS Part\nI, as a clinical trial endpoint designed to measure functional decline in\npeople with MSA; validation of the Chinese version of UMSARS for use in\nclinical trials; and research into cerebrospinal fluid biomarkers that may\nsupport disease detection, differential diagnosis and monitoring.\n\nThe MSA program also includes new data highlighting the broader burden of MSA.\nA US observational database study found significantly higher healthcare costs\nand healthcare resource utilization among people with MSA compared with people\nwith Parkinson’s disease, underscoring the intensive care requirements\nassociated with this rapidly progressing disease.\n\nExploratory clinical data in advanced Parkinson’s disease\nLundbeck will also present new Phase Ib data for Lu AF28996, an\ninvestigational, novel, oral D1-like/D2-like dopamine receptor agonist being\ndeveloped for people with advanced Parkinson’s disease experiencing motor\ncomplications.\n\nThe 18-week open-label Phase Ib trial evaluated safety, tolerability and\nclinical effects in people with inadequately controlled advanced PD\nexperiencing motor fluctuations, with or without dyskinesia (involuntary\nmovements).\n\nThe clinical findings will be complemented by preclinical data exploring the\nrelationship between dose, motor efficacy and dyskinesia in a primate model of\nParkinson’s disease (MPTP-macaque).\n\nLu AF28996 and amlenetug are investigational compounds and have not been\napproved for use by any regulatory authority. Their efficacy and safety have\nnot been established.\n\nLundbeck’s scientific program at MDS:\n\n Data presentations \n Therapeutic  area Presentation content Presentation Type Details \n Multiple system atrophy (MSA)Amlenetug MSA CSF Biomarker Identification: Identification of Candidate Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Using Mass Spectrometry Based Proteomics in CSF Biobank Samples De novo; ePoster (121): Presenter:Pekka Kallunki 4 Oct 13:00-14:00 KST  Hall D, Station 2 Presentation order: 1 \n Multiple system atrophy (MSA)Amlenetug MSA US Healthcare Resource Utilization: Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study De novo; ePoster      (243): Presenter:Amar Mehta 4 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 1 \n Multiple system atrophy (MSA)Amlenetug Chinese UMSARS validation:Validation of the Chinese Version of the Unified Multiple System Atrophy Rating Scale De novo; ePoster      (150): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 5 \n Multiple system atrophy (MSA)Amlenetug Modified UMSARS Psychometrics:Psychometric Assessment of a Modified Version of the Unified Multiple System Atrophy Rating Scale Part I De novo; ePoster      (149): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 4 \n Multiple system atrophy (MSA)Amlenetug MASCOT trial baseline characteristics: Baseline characteristics of a Phase III double-blind, randomized trial of amlenetug for the treatment of multiple system atrophy Late breaker oral presentation; (OPP3): Presenter:Lotte Kjærsgaard 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 11 \n Multiple system atrophy (MSA)Amlenetug CSF α-Synuclein Assay to Differentiate MSA from PD: A CSF C Terminal α Synuclein Assay to Differentiate Multiple System Atrophy From Parkinson’s Disease Oral presentation; (OPP3-G): Presenter:Pekka Kallunki 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 7 \n Parkinson’s disease Lu AF28996  Ph Ib Part B HLR: Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, Results from an 18-week open-label, Phase 1b Trial De novo; ePoster (732)Presenter:Alberto Cucca 6 Oct 09:30-10:30 KST  Hall D, Station 12 \n Presentation order: 4 \n Parkinson’s disease Lu AF28996  Pre-clinical macaque data: Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Reduced Dyskinesia in the MPTP-Macaque Model De novo; ePoster (803) Presenter:Hanna Lindgren 6 Oct 09:30-10:30 KST  Hall D, Station 12 Presentation order: 3 \n\n Sponsored scientific symposium and forum presentation \n Therapeutic area Title Speakers Details \n Multiple system atrophy (MSA) Decoding MSA: From prodromal signs to clinical progression and integrative biomarkers Wassilios Meissner, Horacio Kaufmann Hirohisa Watanabe 5 Oct 12:15-13:15 KSTVenue: ASEM Ballroom 203, 2nd floor \n\n \n\nAbout Multiple System Atrophy (MSA)\nMSA is a rapidly progressing rare condition that causes damage to nerve cells\nin the brain. In a person with MSA, an abnormal build-up of the protein\nα-synuclein is thought to be responsible for damaging the areas of the brain\nthat control balance, movement, and the body's normal functions.(1) MSA is\nseriously debilitating and places a high disease burden on patients. There is\ncurrently no cure for MSA and no available treatment to slow its clinical\nprogression.(2)\n\nSymptoms of MSA usually start between 55 and 60 years of age, and the typical\ntime to death is 8.6 years after symptom onset.(2) Although there are many\ndifferent possible symptoms of MSA, not everyone who is affected will\nexperience all of them. The symptoms of MSA are wide-ranging and include\nmuscle control problems, similar to those of Parkinson's disease.(2) Many\ndifferent functions of the body can be affected, and symptoms including\nurinary incontinence, frequent falling, and unintelligible speech occur within\n3 years of disease onset. MSA is accompanied by reduced capacity to live\nindependently, and death is often due to respiratory problems.\n\nAbout amlenetug \nAmlenetug is a human monoclonal antibody (mAb) that recognizes and binds to\nall major forms of extracellular α-synuclein and thereby intended to prevent\nuptake and inhibit seeding of aggregation. Amlenetug is being developed by\nLundbeck under a joint research and licensing agreement between Lundbeck and\nGenmab A/S.\n\nAbout the MASCOT trial\nMASCOT (NCT06706622) is a Phase III interventional, randomized, double-blind,\nparallel-group, placebo-controlled, optional open-label extension trial that\nwill be conducted in North America, Europe, Asia and Australia.(3)\n\nThe trial comprises two parts: A double-blind period where participants are\nrandomized to receive either high or low doses of amlenetug, or placebo for 72\nweeks, followed by an open-label extension period where all participants\nenrolled in the trial are offered treatment with amlenetug. The aim of the\ntrial is to evaluate the efficacy, safety, and tolerability of amlenetug in\npatients with MSA. Amlenetug is delivered as an intravenous infusion every\nfour weeks.\n\nAbout Parkinson’s disease\nParkinson’s disease is a progressive and disabling neurological disease\ncharacterized by motor symptoms including slowness of movement, tremor and\nrigidity, as well as a range of non-motor symptoms.(4,5)\n\nThere are currently no established treatments that modify the progression of\nPD, and levodopa remains a cornerstone of symptomatic treatment.(6) With\nlong-term levodopa treatment, many people develop motor complications,\nincluding periods when symptoms return or worsen (“OFF-time”) and\ndyskinesia (involuntary movements), which can significantly affect daily\nfunctioning and quality of life.(4-7)\n\nPD is the second most common neurodegenerative disease after Alzheimer’s\ndisease and the most common movement disorder.(7-8) In 2021, an estimated\n11.77 million people worldwide were living with PD, and its prevalence is\nprojected to more than double by 2050.(9) As PD progresses, functional\nindependence can decline and reliance on caregivers and healthcare systems can\nincrease, contributing to a substantial personal, societal and economic\nburden.\n\nAbout Lu AF28996 \nLu AF28996 is an investigational, novel and oral prodrug of a\nD(1)-like/D(2)-like dopamine receptor agonist, with a pharmacologic profile\nthat may enhance dopaminergic striatal signaling in a prolonged manner. It is\nbeing investigated for its potential to improve motor fluctuations and\nlevodopa-induced dyskinesia in people with Parkinson’s disease. Concerted\nactivation of D1- and D2-like dopamine receptors may play an important role in\nmotor control.\n\nLu AF28996 is currently in Phase II clinical development. The DARE2 trial\n(NCT07514858) is evaluating its efficacy, safety and tolerability in adults\nwith Parkinson’s disease experiencing motor fluctuations despite optimized\nnon-invasive symptomatic treatment.(10)\n\nContacts\n\n Anders Crillsen Jens Høyer \n Senior Director, External & Internal Relations Vice President, Head of Investor Relations \n AECE@lundbeck.com JSHR@lundbeck.com \n +45 27 79 12 86 +45 30 83 45 01 \n \n \n \nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn (https://www.linkedin.com/company/lundbeck/).\n\nReferences:\n1. Jellinger KA. J Alzheimers Dis. 2018;62:1141–79\n2. Palma JA, et al. Auton Neurosci. 2018;211:15–25\n3. https://clinicaltrials.gov/study/NCT06706622?intr=Lu%20AF82422&rank=2\n4. Stocchi F, et al. Nat Rev Neurol 2024;20:695–707\n5. Heim B and Poewe W. J Parkinsons Dis 2025;23\n6. Cenci MA. Front Neurol 2014;5:242\n7. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912\n8. GBD. Global, regional, and national burden of neurological disorders during\n1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.\nLancet Neurol 2017;16:877–897\n9. Luo Y, et al. Front Aging Neurosci 2025;16:1498756.\n10.\nhttps://clinicaltrials.gov/study/NCT07514858?term=nct07514858%20&viewType=Card&rank=1\n \nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-showcase-progress-across-its-movement-disorders-pipeline-with-data-in-multiple-system-at%2Cc4403628\n\nMDS 2026 Final (https://mb.cision.com/Main/18215/4403628/4298745.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-10-02T06:00:11.760154638Z","server_sent_at_ms":1790920811760},"received_at":"2026-10-02T06:00:11.812Z","source_url":"https://news.cision.com/h--lundbeck-a-s/r/lundbeck-to-showcase-progress-across-its-movement-disorders-pipeline-with-data-in-multiple-system-at%2Cc4403628"},"analysis":{"id":"147647","press_release_id":"159033","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["MASCOT Phase III efficacy readout not until Q3 2027 -- binary risk remains far off","amlenetug and Lu AF28996 are investigational with unestablished efficacy and safety"],"eventType":"clinical_trial","narrative":"Lundbeck will present movement disorders pipeline data at the MDS 2026 Congress in Seoul (4-8 October), headlined by a late-breaking oral presentation on baseline characteristics of the Phase III MASCOT trial of amlenetug in multiple system atrophy.\n\nMASCOT has enrolled 401 participants across both MSA subtypes, with a 72-week double-blind treatment period and results expected in Q3 2027.\n\nLundbeck will also show exploratory 18-week Phase Ib data for Lu AF28996, an oral dopamine receptor agonist for difficult-to-treat motor complications in advanced Parkinson's disease, now in Phase II via the DARE2 trial.\n\nBoth compounds remain investigational with no regulatory approval; this is a scientific-visibility event, not a data readout.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Pipeline visibility event only -- keep MASCOT Q3 2027 readout on the calendar as the real catalyst."},"keyFigures":{"drugName":"amlenetug (MSA); Lu AF28996 (Parkinson's disease)","phaseOfTrial":"Phase III (MASCOT/MSA); Phase Ib and Phase II (DARE2, Lu AF28996)","customDimensions":{"mascot_enrolled":401,"phase1b_duration_weeks":18,"mascot_results_expected":"Q3 2027","mascot_treatment_duration_weeks":72}},"quotedText":"The breadth of research we are presenting at MDS reflects our commitment to advancing potential new medicines while strengthening the scientific understanding of the biomarkers and clinical tools needed to support progress for patients.","namedEntities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development"},{"name":"Lotte Kjærsgaard","role":"MASCOT oral presentation presenter"},{"name":"Pekka Kallunki","role":"ePoster/oral presenter (CSF biomarkers)"},{"name":"Alberto Cucca","role":"Phase Ib ePoster presenter"},{"name":"Horacio Kaufmann","role":"symposium speaker"}],"products":["amlenetug","Lu AF28996","mUMSARS Part I","UMSARS"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Genmab A/S","relationship":"licensing partner (amlenetug)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine conference data showcase of ongoing pipeline programs; no new efficacy or safety results, regulatory events, or guidance changes. MASCOT Phase III readout remains on track for Q3 2027."},"tickerRelevance":{"others":[],"primary":"HLUNA"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"foreign-listed mid-cap pharma","eventGravity":"conference-data-showcase","nextCatalyst":"MASCOT Phase III readout Q3 2027","issuerAuthored":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Lundbeck will present movement disorders pipeline data at the MDS 2026 Congress in Seoul (4-8 October), headlined by a late-breaking oral presentation on baseline characteristics of the Phase III MASCOT trial of amlenetug in multiple system atrophy.\n\nMASCOT has enrolled 401 participants across both MSA subtypes, with a 72-week double-blind treatment period and results expected in Q3 2027.\n\nLundbeck will also show exploratory 18-week Phase Ib data for Lu AF28996, an oral dopamine receptor agonist for difficult-to-treat motor complications in advanced Parkinson's disease, now in Phase II via the DARE2 trial.\n\nBoth compounds remain investigational with no regulatory approval; this is a scientific-visibility event, not a data readout.","key_figures":{"drugName":"amlenetug (MSA); Lu AF28996 (Parkinson's disease)","phaseOfTrial":"Phase III (MASCOT/MSA); Phase Ib and Phase II (DARE2, Lu AF28996)","customDimensions":{"mascot_enrolled":401,"phase1b_duration_weeks":18,"mascot_results_expected":"Q3 2027","mascot_treatment_duration_weeks":72}},"named_entities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development"},{"name":"Lotte Kjærsgaard","role":"MASCOT oral presentation presenter"},{"name":"Pekka Kallunki","role":"ePoster/oral presenter (CSF biomarkers)"},{"name":"Alberto Cucca","role":"Phase Ib ePoster presenter"},{"name":"Horacio Kaufmann","role":"symposium speaker"}],"products":["amlenetug","Lu AF28996","mUMSARS Part I","UMSARS"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Genmab A/S","relationship":"licensing partner (amlenetug)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T06:00:20.006Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"foreign-listed mid-cap pharma","eventGravity":"conference-data-showcase","nextCatalyst":"MASCOT Phase III readout Q3 2027","issuerAuthored":true}},"durationMs":8179,"modelName":"glm-5.3-flashx"}}